Shingo Tamura

Fukuoka, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 37 publications

A study to learn how well the combination of encorafenib and binimetinib works and how safe it is in adults with thyroid cancer: a plain language summary.

A study to learn how well the combination of encorafenib and binimetinib works and how safe it is in adults with thyroid cancer: a plain language summary.

Journal: Future oncology (London, England)

Published: March 24, 2026

Encorafenib plus binimetinib for BRAF V600-mutated thyroid cancer in Japan: final analysis.

Encorafenib plus binimetinib for BRAF V600-mutated thyroid cancer in Japan: final analysis.

Journal: International journal of clinical oncology

Published: March 12, 2026

Health-related quality of life with encorafenib plus binimetinib for BRAF V600E thyroid cancer.

Health-related quality of life with encorafenib plus binimetinib for BRAF V600E thyroid cancer.

Journal: European thyroid journal

Published: September 24, 2025

Clinical outcomes and genomic alterations in patients with metastatic malignant phyllodes tumors.

Clinical outcomes and genomic alterations in patients with metastatic malignant phyllodes tumors.

Journal: Japanese journal of clinical oncology

Published: August 14, 2025

A Phase 2 Study of Encorafenib in Combination with Binimetinib in Patients with Metastatic BRAF-Mutated Thyroid Cancer in Japan.

A Phase 2 Study of Encorafenib in Combination with Binimetinib in Patients with Metastatic BRAF-Mutated Thyroid Cancer in Japan.

Journal: Thyroid : official journal of the American Thyroid Association

Published: February 12, 2024

Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022.

Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022.

Journal: International journal of clinical oncology

Published: February 09, 2024

Efficacy of anti-PD-1 monotherapy for recurrent or metastatic olfactory neuroblastoma.

Efficacy of anti-PD-1 monotherapy for recurrent or metastatic olfactory neuroblastoma.

Journal: Frontiers in oncology

Published: January 30, 2024

Effectiveness and safety of primary prophylaxis of granulocyte colony-stimulating factor during dose-dense chemotherapy for urothelial cancer: Clinical Practice Guidelines for the Use of G-CSF 2022.

Effectiveness and safety of primary prophylaxis of granulocyte colony-stimulating factor during dose-dense chemotherapy for urothelial cancer: Clinical Practice Guidelines for the Use of G-CSF 2022.

Journal: International journal of clinical oncology

Published: January 19, 2024

Spatial dynamics of CD39+CD8+ exhausted T cell reveal tertiary lymphoid structures-mediated response to PD-1 blockade in esophageal cancer.

Spatial dynamics of CD39+CD8+ exhausted T cell reveal tertiary lymphoid structures-mediated response to PD-1 blockade in esophageal cancer.

Journal: Nature communications

Published: December 13, 2023

Survival outcomes including salvage therapy of adult head and neck para-meningeal rhabdomyosarcoma: a multicenter retrospective study from Japan.

Survival outcomes including salvage therapy of adult head and neck para-meningeal rhabdomyosarcoma: a multicenter retrospective study from Japan.

Journal: BMC cancer

Published: August 05, 2023

Early Phase Persistent Changes in the White Blood Cell Fraction in Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab: A Multicenter Retrospective Study.

Early Phase Persistent Changes in the White Blood Cell Fraction in Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab: A Multicenter Retrospective Study.

Journal: Anticancer research

Published: August 01, 2023

Preferential B cell differentiation by combined immune checkpoint blockade for renal cell carcinoma is associated with clinical response and autoimmune reactions.

Preferential B cell differentiation by combined immune checkpoint blockade for renal cell carcinoma is associated with clinical response and autoimmune reactions.

Journal: Cancer immunology, immunotherapy : CII

Published: February 01, 2023

Showing 1-12 of 37

Last Updated: 09/26/2026